VX-272 dose escalation in healthy adults
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects
Run by Vertex Pharmaceuticals Incorporated · NCT07437105 · Data updated 2026-11-12
This will test single and multiple increasing doses of the experimental drug VX-272 in healthy adults to see how safe it is and how the body handles it.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | Vertex Pharmaceuticals Incorporated Industry-sponsored |
| Locations | 1 site (Tempe, Arizona) |
| Status | Recruiting |
| Started | February 25, 2026 |
| Main results expected | June 26, 2027 |
| Study ends | June 26, 2027 |
| Registry record updated | September 23, 2026 |
| Trial ID | NCT07437105 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy adults over 50 kg with a BMI between 18.0 and 32.0 kg/m2 who are not of childbearing potential and have no recent febrile illness or conditions affecting drug absorption.
✕Probably not a fit
People with active illnesses, those of childbearing potential, those weighing 50 kg or less, or individuals with conditions that affect drug absorption — and patients with cystic fibrosis seeking immediate treatment benefit — are unlikely to receive direct therapeutic benefit from this healthy-volunteer Phase 1 study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1, randomized placebo-controlled trial gives single and multiple ascending doses of VX-272 to healthy adult volunteers to collect safety, tolerability, and pharmacokinetic data. Participants must meet weight and BMI criteria and be non-childbearing potential, and those with recent febrile illness or conditions affecting absorption are excluded. Dosing cohorts will escalate based on predefined safety criteria and pharmacokinetic results. The data will inform dose selection and safety monitoring for later studies in people with cystic fibrosis.
Why it matters
Potential benefit: If VX-272 is safe and has favorable pharmacokinetics, it could enable development of a new treatment option for people with cystic fibrosis.
How similar studies have gone: Dose-escalation safety and pharmacokinetic trials in healthy volunteers are a standard early-phase approach that has supported the development of other cystic fibrosis drugs, but VX-272 itself appears to be first-in-human with no prior published human results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2) * A total body weight of more than (\>) 50 kg * Male and Female participants of non-childbearing potential Key Exclusion Criteria: * History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug * Any condition possibly affecting drug absorption Other protocol defined Inclusion/Exclusion criteria may apply.
Where it's running
-
Celerion - Tempe
Tempe, Arizona, United States Recruiting
Study contacts
- Study coordinator: Medical Information
- Email: medicalinfo@vrtx.com
- Phone: 617-341-6777
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Inhaled CFTR mRNA for cystic fibrosis in Chinese patients aged 12 and older
This trial tests inhaled BMD003, a CFTR mRNA therapy, to see if it's safe and shows early signs of benefit in Chinese people 12 years and up with cystic fibrosis.
-
Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis
This project will see how common smoking, exposure to secondhand smoke, and vaping are among adults with cystic fibrosis followed at the Strasbourg Adult CF Center.
-
Dose escalation of VX-581 to check safety and drug levels in healthy adults
The trial will test increasing doses of VX-581 in healthy adults to see if it is safe and to measure how the body absorbs and clears the drug.
-
PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care
This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.
-
Collecting sputum samples at home for cystic fibrosis patients
This study is testing if collecting sputum samples at home can help people with cystic fibrosis better identify lung infections compared to traditional methods done at the clinic.
-
New device for sweat testing in cystic fibrosis patients
This study is testing a new device that measures sweat to see if it can help doctors better diagnose cystic fibrosis in patients, healthy individuals, and carriers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.